A trial vaccine for patients suffering from aggressive brain cancer has proven effective at extending survival during its Phrase 3 of trials.
Vaccine DCVax-L is currently in its third phase of trials at London’s King’s College Hospital, and targets a type of cancer called glioblastoma.
The vaccine works by helping the body’s immune system recognise and attack the deadly cancer cells. Sufferers in the trials have been living for months or years beyond what was originally projected.
The results were published in the Journal of American Medical Association Oncology, with a statement from the college saying that this offers fresh hope to patients battling with glioblastoma.
“The vaccine was shown to prolong life, and interestingly so in patients traditionally considered to have poorer prognosis” read the statement. All of the participants in the trial underwent the standard treatment for glioblastoma of surgery followed by radiotherapy and chemotherapy.
“The long-term survivor group in particular has the potential to further teach us about the basic biology of glioblastomas, given that many patients in this group did not have the usual expected characteristics for good outcomes.”